Papillary Thyroid Micro Carcinoma: The Incidence of High-Risk Features and Its Prognostic Implications

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2019 Mar 5

PMID 30828316

Citations 9

Authors

Rui Gao

Xi Jia

Yiqian Liang

Kun Fan

Xiaoxiao Wang

Yuanbo Wang

Lulu Yang

Aimin Yang

Guangjian Zhang

Affiliations

Soon will be listed here.

Abstract

The current management of papillary thyroid micro carcinoma (PTMC) has become more conservative. However, high-risk characteristics that can only be revealed post-surgically exist. Patients and clinicians need to estimate the risks and understand the prognostic meaning of these factors. We retrospectively analyzed 246 consecutive patients with PTMC who underwent surgery at our institution between 2015 and 2017. Clinical and histopathological parameters that may indicate recurrent disease were investigated. The responses to therapy in cases with different risks of recurrence were analyzed. A total of 79.26% (195/246) of patients received total thyroidectomy (TT), of whom 177 (90.77%) also received central lymph node dissection. Radioiodine ablation (RAI) was applied in 64.23% (158/246) of patients. Intermediate-high risk features were identified in 27.64% (68/246) after primary treatment. After a median follow-up of 18 months (range, 6-39 months), 121 of 158 (76.58%) patients who received TT+RAI were evaluated as an excellent response. An incomplete response (IR) was observed in 14.56% (23/158) of this group of PTMC. Multivariate analysis identified extra thyroid extension ( = 0.001) and intermediate-high risk stratification ( = 0.014) as significant and independent risk factors for an IR. A total of 27.64% of PTMC cases evaluated as a low risk of recurrence pre-surgery showed intermediate to high risk disease post-surgery, and this leads to a higher rate of IR.

Citing Articles

Is conservative treatment always safe in unifocal clinically T1a/node-negative papillary thyroid carcinoma?.

Pennestri F, Procopio P, Laurino A, Martullo A, Santoro G, Gallucci P World J Surg. 2024; 49(1):187-197.

PMID: 39631795 PMC: 11711119. DOI: 10.1002/wjs.12440.

Comparison of the value of ultrasound-guided fine needle aspiration biopsy and contrast-enhanced ultrasound in different sizes of thyroid nodules.

Liu Q, Ouyang L, Zhang S, Yang Y Medicine (Baltimore). 2024; 103(39):e39843.

PMID: 39331869 PMC: 11441858. DOI: 10.1097/MD.0000000000039843.

Incidental thyroid carcinoma in an endemic goiter area in Italy: histopathological features and predictors of a common finding.

Chiefari E, Innaro N, Gervasi R, Mirabelli M, Giuliano S, Donnici A Endocrine. 2024; 84(2):589-597.

PMID: 38217773 PMC: 11076372. DOI: 10.1007/s12020-023-03659-2.

A clinical and molecular pathology prediction model for central lymph node metastasis in cN0 papillary thyroid microcarcinoma.

Ma T, Wang L, Zhang X, Shi Y Front Endocrinol (Lausanne). 2023; 14:1075598.

PMID: 36817603 PMC: 9932534. DOI: 10.3389/fendo.2023.1075598.

The efficacy and safety of microwave ablation versus conventional open surgery for the treatment of papillary thyroid microcarcinoma: a systematic review and meta-analysis.

Wu X, Jiang Z, Liu J, Liu N, Hu Q, Xiong Y Gland Surg. 2022; 11(6):1003-1014.

PMID: 35800741 PMC: 9253192. DOI: 10.21037/gs-22-243.

References

Yamashita H, Noguchi S, Murakami N, Toda M, Uchino S, Watanabe S . Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999; 86(5):842-9. DOI: 10.1002/(sici)1097-0142(19990901)86:5<842::aid-cncr21>3.0.co;2-x. View

Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K . An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003; 13(4):381-7. DOI: 10.1089/105072503321669875. View

Hay I, Grant C, Van Heerden J, Goellner J, Ebersold J, Bergstralh E . Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992; 112(6):1139-46; discussion 1146-7. View

Page C, Biet A, Boute P, Cuvelier P, Strunski V . 'Aggressive papillary' thyroid microcarcinoma. Eur Arch Otorhinolaryngol. 2009; 266(12):1959-63. DOI: 10.1007/s00405-009-0952-5. View

Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y . Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011; 21(7):707-16. DOI: 10.1089/thy.2010.0355. View

Soyluk O, Boztepe H, Aral F, Alagol F, Ozbey N . Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial.... Thyroid. 2011; 21(12):1301-8. DOI: 10.1089/thy.2011.0122. View

Zhang L, Wei W, Ji Q, Zhu Y, Wang Z, Wang Y . Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012; 97(4):1250-7. DOI: 10.1210/jc.2011-1546. View

Ardito G, Revelli L, Giustozzi E, Salvatori M, Fadda G, Ardito F . Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med. 2012; 38(1):25-8. DOI: 10.1097/RLU.0b013e318279bc65. View

Lang B, Ng S, Lau L, Cowling B, Wong K, Wan K . A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid. 2013; 23(9):1087-98. DOI: 10.1089/thy.2012.0608. View

10.

Avram A, Fig L, Frey K, Gross M, Wong K . Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?. J Clin Endocrinol Metab. 2013; 98(3):1163-71. DOI: 10.1210/jc.2012-3630. View

11.

Castagna M, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C . Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013; 169(1):23-9. DOI: 10.1530/EJE-12-0954. View

12.

Kuo E, Goffredo P, Sosa J, Roman S . Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid. 2013; 23(10):1305-11. PMC: 3783926. DOI: 10.1089/thy.2012.0563. View

13.

Wong C, Lang B . A cost-utility analysis for prophylactic central neck dissection in clinically nodal-negative papillary thyroid carcinoma. Ann Surg Oncol. 2013; 21(3):767-77. DOI: 10.1245/s10434-013-3398-3. View

14.

Vigneri R, Malandrino P, Vigneri P . The changing epidemiology of thyroid cancer: why is incidence increasing?. Curr Opin Oncol. 2014; 27(1):1-7. DOI: 10.1097/CCO.0000000000000148. View

15.

Soydal C, Araz M, Ozkan E, Arslantas E, Kucuk O, Aras G . Assessment of recurrence rates in papillary thyroid microcarcinoma patients with and without histopathological risk factors after radioiodine ablation treatment. Nucl Med Commun. 2014; 36(2):109-13. DOI: 10.1097/MNM.0000000000000230. View

16.

Ruel E, Thomas S, Dinan M, Perkins J, Roman S, Sosa J . Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015; 100(4):1529-36. PMC: 4399282. DOI: 10.1210/jc.2014-4332. View

17.

Frangos S, Iakovou I, Marlowe R, Eftychiou N, Patsali L, Vanezi A . Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. Eur J Nucl Med Mol Imaging. 2015; 42(13):2045-55. DOI: 10.1007/s00259-015-3124-4. View

18.

Brito J, Ito Y, Miyauchi A, Tuttle R . A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid. 2015; 26(1):144-9. PMC: 4842944. DOI: 10.1089/thy.2015.0178. View

19.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

20.

Verburg F, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M . Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016; 43(6):1001-5. DOI: 10.1007/s00259-016-3327-3. View